Asthika Goonewardene
Stock Analyst at Truist Securities
(1.24)
# 3,391
Out of 4,755 analysts
90
Total ratings
35%
Success rate
-14.29%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asthika Goonewardene
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IOVA Iovance Biotherapeutics | Maintains: Buy | $25 → $15 | $3.81 | +294.22% | 6 | Mar 3, 2025 | |
| CRGX CARGO Therapeutics | Downgrades: Hold | $32 → $7 | $3.78 | +85.43% | 3 | Jan 30, 2025 | |
| EXEL Exelixis | Maintains: Buy | $42 → $43 | $38.45 | +11.85% | 8 | Jan 27, 2025 | |
| IGMS IGM Biosciences | Maintains: Hold | $12 → $2 | $1.26 | +59.36% | 8 | Jan 10, 2025 | |
| BNTX BioNTech SE | Initiates: Buy | $172 | $110.68 | +55.41% | 1 | Jan 10, 2025 | |
| SMMT Summit Therapeutics | Initiates: Buy | $35 | $18.83 | +85.87% | 1 | Jan 8, 2025 | |
| ACLX Arcellx | Maintains: Buy | $87 → $136 | $63.65 | +113.69% | 5 | Nov 12, 2024 | |
| GILD Gilead Sciences, Inc. | Maintains: Hold | $83 → $97 | $114.70 | -15.43% | 1 | Nov 8, 2024 | |
| GMAB Genmab | Maintains: Buy | $53 → $50 | $23.24 | +115.19% | 13 | Sep 9, 2024 | |
| STRO Sutro Biopharma | Maintains: Buy | $18 → $15 | $1.41 | +967.62% | 6 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $17 → $14 | $1.78 | +686.52% | 6 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $44 | $10.12 | +334.78% | 1 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $88 | $33.53 | +162.49% | 1 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $69 → $88 | $44.27 | +98.80% | 2 | Jun 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $4 | $1.73 | +131.88% | 5 | May 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 | $1.07 | +1,684.04% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $9 | $0.50 | +1,712.69% | 3 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $1.36 | +2,852.03% | 4 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $27 | $0.84 | +3,115.05% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $9 | $1.77 | +408.47% | 3 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Hold | $120 | $17.04 | +604.27% | 1 | Apr 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $100 → $60 | $1.06 | +5,559.84% | 3 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $15 | $0.70 | +2,039.80% | 4 | Aug 23, 2022 |
Iovance Biotherapeutics
Mar 3, 2025
Maintains: Buy
Price Target: $25 → $15
Current: $3.81
Upside: +294.22%
CARGO Therapeutics
Jan 30, 2025
Downgrades: Hold
Price Target: $32 → $7
Current: $3.78
Upside: +85.43%
Exelixis
Jan 27, 2025
Maintains: Buy
Price Target: $42 → $43
Current: $38.45
Upside: +11.85%
IGM Biosciences
Jan 10, 2025
Maintains: Hold
Price Target: $12 → $2
Current: $1.26
Upside: +59.36%
BioNTech SE
Jan 10, 2025
Initiates: Buy
Price Target: $172
Current: $110.68
Upside: +55.41%
Summit Therapeutics
Jan 8, 2025
Initiates: Buy
Price Target: $35
Current: $18.83
Upside: +85.87%
Arcellx
Nov 12, 2024
Maintains: Buy
Price Target: $87 → $136
Current: $63.65
Upside: +113.69%
Gilead Sciences, Inc.
Nov 8, 2024
Maintains: Hold
Price Target: $83 → $97
Current: $114.70
Upside: -15.43%
Genmab
Sep 9, 2024
Maintains: Buy
Price Target: $53 → $50
Current: $23.24
Upside: +115.19%
Sutro Biopharma
Aug 16, 2024
Maintains: Buy
Price Target: $18 → $15
Current: $1.41
Upside: +967.62%
Aug 9, 2024
Reiterates: Buy
Price Target: $17 → $14
Current: $1.78
Upside: +686.52%
Jun 24, 2024
Maintains: Buy
Price Target: $50 → $44
Current: $10.12
Upside: +334.78%
Jun 17, 2024
Initiates: Buy
Price Target: $88
Current: $33.53
Upside: +162.49%
Jun 4, 2024
Maintains: Buy
Price Target: $69 → $88
Current: $44.27
Upside: +98.80%
May 21, 2024
Maintains: Buy
Price Target: $5 → $4
Current: $1.73
Upside: +131.88%
May 16, 2024
Maintains: Buy
Price Target: $19
Current: $1.07
Upside: +1,684.04%
Feb 29, 2024
Upgrades: Buy
Price Target: $9
Current: $0.50
Upside: +1,712.69%
Sep 6, 2023
Reiterates: Buy
Price Target: $40
Current: $1.36
Upside: +2,852.03%
Sep 6, 2023
Reiterates: Buy
Price Target: $27
Current: $0.84
Upside: +3,115.05%
Aug 17, 2023
Maintains: Buy
Price Target: $6 → $9
Current: $1.77
Upside: +408.47%
Apr 5, 2023
Reinstates: Hold
Price Target: $120
Current: $17.04
Upside: +604.27%
Aug 23, 2022
Maintains: Hold
Price Target: $100 → $60
Current: $1.06
Upside: +5,559.84%
Aug 23, 2022
Maintains: Buy
Price Target: $19 → $15
Current: $0.70
Upside: +2,039.80%